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Abstract
Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal
models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of
human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous
neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 22/2 cC2/2 mice subjected to FeCl3
thrombosis mediated stroke were intracranially injected with 26105 hMAPCs or hMSCs 2 days after stroke and followed for
up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison with PBS-
treated animals, hMSC and hMAPC grafted animals demonstrated significantly decreased loss of brain tissue. This was
associated with increased angiogenesis, diminished inflammation and a glial-scar inhibitory effect. Moreover, enhanced
proliferation of cells in the subventricular zone (SVZ) and survival of newly generated neuroblasts was observed.
Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in
comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for the
treatment of stroke.
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Introduction
The use of cell therapy for the treatment of neurological
disorders is currently an area of intense research. Stroke
represents a particularly attractive target being the third leading
cause of death and disability in western countries. There is a
lack of successful therapies and only the use of recombinant
tissue plasminogen activator has demonstrated some efficacy,
which is actually restricted by the narrow window of therapeutic
efficacy. Critical to the success of cell therapies is the selection
and mode of delivery of cell populations. Various cell types
including neural stem cells, endothelial precursor cells, cord
blood cells and mesenchymal stem cells (MSC) have been tested
as therapeutic agents, providing compelling evidence that
application of stem/progenitor cells is safe and effective in
animal models of stroke [1,2,3,4,5,6]. However, before embark-
ing on clinical trials in stroke patients a number of issues need
to be addressed [7].
Similar to what has been observed in other ischemic diseases
such as myocardial infarction, the hope that stem/progenitor cells
could contribute to the restoration of the damaged tissue seems
currently unrealistic [8,9]. The more likely explanation for the
beneficial effects observed in animal models is that the transplant-
ed cells provide the damaged tissue with an improved microen-
vironment through the secretion of cytokines and trophic factors
(VEGF, BDNF, bFGF, NGF…) [2,10,11,12,13]. Such molecules
may reduce apoptotic cell death, promote angiogenesis, attenuate
inflammation, reduce glial-scar formation and activate endoge-
nous brain remodeling [1,11,14,15,16,17].
From all the cell types tested, MSCs have emerged as one of the
leading candidate populations in stroke management, as they are
easily obtained from a range of tissues (including bone marrow, fat
and other somatic tissues [18]), can be rapidly expanded in vitro
while maintaining their potential to differentiate into multiple
tissues [19,20,21]. An additional advantage is that MSCs are
immune-privileged and thus could be explored in the allogeneic
setting with a reduced risk of rejection. In fact a limited number of
clinical studies have safely transplanted human MSCs in patients
with stroke with promising results [22,23,24].
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Recently, multipotent adult progenitor cells (MAPCs), a
subpopulation of stem cells isolated from bone marrow, have
been described and characterized. Human MAPCs are multipo-
tent stem cells that have been shown to differentiate into various
mesodermal cell types, with a remarkable proliferative capacity in
culture [25]. In particular, their vascular potential in vitro and in
vivo has been demonstrated which make them an attractive
candidate for novel cell-based treatment of ischemic diseases.
Moreover MAPCs are also immune-privileged [26,27,28,29,30].
The current study was designed to examine whether ischemic
brain injury can be ameliorated by hMAPC administration, in
comparison with hMSC transplantation in a thrombosis middle
cerebral artery occlusion (MCAo) model.
Materials and Methods
Preparation of Cells
hMSCs clone JN1 and hMAPC clone B30/E2 were provided in
frozen vials by Athersys, Inc. Cells were prepared under GMP
(good manufacturing practice) as previously described [31]. At the
time of transplantation, cells were thawed, resuspended in PBS
and cell density was adjusted to a final concentration of 16105
cells/3.0 ml.
For fluorescence-activated cell sorting (FACS) analysis, cells
were detached with 0.05% trypsin-EDTA and washed with PBS.
hMAPCs and hMSCs ranging in number between 16105 to
26105 hMSCs were incubated with fluorescent conjugated
primary antibodies for 15 min in the dark at room temperature
(RT). The following antibodies were used: CD44-FITC, CD45-
FITC, HLA-II-PE, CD144-FITC, CD34-FITC, HLA-I-APC,
CD105-APC, CD140a-PE, CD90-APC, CD73-PE, CD117-PE,
and CD31-PE, and their corresponding isotype controls (all from
BD Pharmingen). Cells were fixed with 4% paraformaldehyde
(PFA) at 4uC (Figure S1) (Roobrouck et al., 2011).
Animals and Surgical Procedures
All experiments were performed in accordance with the
‘‘Principles of Laboratory Animal Care’’, and all procedures
involving animals were approved by the Animal Ethical Commit-
tee of our Institute (University of Navarra Institutional Committee
on the Care and Use of Laboratory Animals). Mice were kindly
provided by Dr. Mamoru (from the Central Institute for
Experimental Animals, Kawasaki, Japan), bred and housed in a
temperature-controlled room with access to food and water ad
libitum Thrombotic stroke was induced in adult (7-week-old) male
BALB/Ca-RAG22/2cc2/2 mice under controlled conditions.
Ferric chloride thrombosis stroke model. Mice were
anesthetized with 80–100 mg/kg i.p ketamine hydrochloride and
10-mg/kg i.p xylazine. Animals were placed in the right lateral
position, the skin between the right eye and the right ear was
incised, and the temporal muscle was retracted. A small
craniotomy was performed, the dura was excised, and the middle
cerebral artery (MCA) was exposed. Thrombus was induced by
topical application of a small strip of filter paper soaked with 20%
Ferric Chloride (Sigma-Aldrich) with the adventitial surface of the
vessel. After 1 min of exposure the filter paper was removed and
the vessel was washed with saline. Soft tissues were allowed to fall
back into place and the skin was sutured [32]; [33,34]. The sham
group underwent similar operative procedure except that 0.9%
saline was used instead of 20% ferric chloride. Animals received
analgesia (Ketoprofen 5 mg/Kg) on the day of the surgery and
each day thereafter, as well as antibiotic treatment (Enrofloxacin
25 mg/Kg) for 5 days.
Cell transplantation. After stroke, mice were randomly
assigned to the treatment groups. Stereotaxic surgery was
performed under anesthesia 2 days after stroke for mice recovery
from previous stroke surgery and regarding potential human
transplantation. Mice were given two 3.0 ml injections of hMSCs
or hMAPCs or PBS (16105 cells/3 ml; or 3.0 ml of PBS) along the
anterior-posterior axis at the following coordinates: 1) A–P:1.18;
M–L:1.5; D–V:2.5; 2) A–P:21.0; M–L:2.5; D–V: 2.6 [35]. A
micro-infusion pump was used to control the speed of delivery at
0.5 ml/min. The needle was left in situ for 10 min post-injection
before being slowly removed.
All the groups and a sham, which was not subjected to stroke
and cell transplantation, were analyzed at different time points
after cell transplantation (2 days, 4 days, 7 days and 28 days) (n = 7
per group and time point: n = 4 for immunohistochemical analysis
and n= 3 for semithin section analysis; n = 28 animals per group)
(Figure S2).
Immunohistochemistry and Morphometric Analysis
At sacrifice, mice were intracardially perfused with PBS
followed by 4% PFA. Brains were removed, postfixed overnight
in 4% PFA and cryoprotected in 15% sucrose overnight (ON) at
4uC. Subsequently, brains were frozen and cryostat-sectioned
coronally at 14 mm. Ten serial series (containing one section out of
every 10) were prepared for volume analysis and immunohisto-
chemical quantifications. Analyses were performed in a blinded
fashion.
Measurement of cavitation. Tissue loss volume was mea-
sured in 4 mice per group 4 weeks after 28 days PBS or cell
transplantation (Figure S2). At this time point necrotic tissue has
been replaced by a cavity (or cyst), thereby dropping inflammation
and edema [32]. One of each 10 serial sections per animal was
thawed at RT for 20 min, washed with PBS and stained with
0.25% thionin (Sigma-Aldrich) at 60uC for 5 min. Then, sections
were rinsed in water and dehydrated through graded alcohols,
cleared in xylene and coverslipped in DPX mounting media
(VWR Prolabo). The area of both hemispheres (mm2) was
calculated by tracing the area on the computer screen. To reduce
errors associated with processing of tissue for histological analysis,
the area of cavitation in each section was presented as the
percentage of the cavitation in comparison to the area of the
contralateral hemisphere.
Immunofluorescence. For BrdU immunostaining, sections
were pre-treated with 2N HCl (30 min at 37uC) and then rinsed
for 15 min in 0.1M-borate buffer [pH 8.5]. For CD31 immuno-
staining, sections were pre-treated with 2% trypsin in 0.1% CaCl2
(7 min at 37uC). For NG2-Chondroitin Sulfate Proteoglycan
(NG2-CSP) and fibronectin immunostaining sections were pre-
treated with citrate buffer (20 min at 60uC). Sections were rinsed
in PBS and incubated in blocking solution, followed by an ON
incubation at 4uC with the primary antibody: mouse anti-BrdU,
1:50 (DakoCytomation), mouse anti-human nuclei HuNu, 1:100
(DakoCytomation), rat anti-CD31, 1:500 (BD Biosciences), mouse
anti-NG2-CSP, 1:200 (Millipore), mouse anti-fibronectin, 1:50
(Millipore) or goat anti-Doublecortin DCX, 1:200 (Santa Cruz
Biotechnology). Subsequently, sections were washed and incubat-
ed for 1 hr with the appropriate secondary antibody: mouse-Cy3
or rabbit-FITC, goat-Cy3, 1:200 (Jackson Immunoresearch), or
biotinylated rabbit anti-rat IgG antibody, 1:300 (DakoCytoma-
tion). For CD31, the tyramide signal amplification kit, (TSA)
(Perkin Elmer) was used according to the manufacturers instruc-
tions. The sections were mounted using vectashield with DAPI
(Vector).
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Immunohistochemistry. For microglia staining, sections
were preincubated in endogenous peroxidase blocking solution,
an incubated in blocking solution, followed by an overnight
incubation at 4uC with rabbit anti-Iba1, 1:200 (WAKO). The
sections were then washed and incubated for 90 min with
biotinylated goat anti-rabbit, 1:250 (VECTOR) and then for
45 min with Avidin-Biotin-Peroxides Complex (ABC, 1:250,
VECTOR). The antibody staining was visualized with 0.05%
DAB (Sigma) and sections were dehydrated and mounted with
Eukit mounting media (VWR).
Neovascularization. To estimate the blood vessel density
after stroke, five to seven CD31 stained, 14 mm coronal sections
per animal (n = 4 in each group), spaced 140 mm apart were
analyzed (Figure S2). Blood vessel density estimation was
performed in the ischemic boundary region using an Axioplan
2-Zeiss automated microscope. This region was delineated from
the edge of the pan-necrotic cystic cavity approximately 400 mm
into the adjacent cortex. Within these boundaries four randomly
chosen fields at 10x magnification were analyzed. The acquisition
of the images was performed with a macro designed in
Metamorph 6.3r6H. Blood vessel density was estimated as the
percentage of CD31 positive area.
Inflammation. Microglia activation was evaluated by mea-
suring shape transformation according to previously described
criteria [36,37]. A total of 25 microglial cells were randomly
selected in a 300 mm wide area at the peri-infarct zone per section,
in six coronal sections spaced 140 mm apart (150 microglial cells
per animal) (n = 4 per group) 4 days after cell transplantation
(Figure S2). The soma was placed in the center of a grid of 10
concentric circles, 5 mm apart and the number of intersections
between cytoplasmic processes and grid lines was registered.
Scar-inhibition. For qualitative analysis, fibronectin and
NG2-CSP two-dimensional pseudocolor images (4095 color levels)
were gathered using Nikon C-HGFI fluorescence microscope.
Quantification was assessed by measuring the percentage of
threshold area occupied by NG2-CSP-positive or fibronectin
staining in relation to the whole-tissue area in the peri-ischemic
area. Approximately 8 fields of the ischemic cerebral cortex from
five to eight coronal brain sections of four animals per group were
analysed. Analysis was performed by optical density measurements
(binary image processing of black and white), obtaining the
percentage of NG2-CSP or fibronectin per visual field area
analysed with the Image J 1.42 software (NIH).
SVZ proliferation. To evaluate the activation of SVZ
proliferation, a single dose of BrdU (50 mg/kg) was injected 2
hours before sacrifice to mice in each group (n = 4; sham, PBS,
hMSCs and hMAPCs), which were sacrificed at different time
points after transplantation (2 days, 4 days, 7 days and 28 days).
BrdU positive cells in the SVZ were counted blindly using five to
seven 14 mm coronal sections per animal (n = 5–7), which were
spaced 140 mm apart from one another (Figure S2). Cells were
counted under high power on an Axio imager M1 Zeiss
microscope. Results were expressed as the average number of
BrdU-positive cells per section.
Endogenous neuroblast survival. Double labeling with
HuNu and DCX (n= 4 in each group), in the peri-infarct 28
days after cell transplantation was performed (Figure S2).
For systematic random sampling in design-based stereological
cell counting, four coronal brain sections per mouse were
selected, spaced 140 mm apart across the same region of interest
in each animal (from Bregma: +0.7 mm to 2 0.7 mm). For
multi-stage random sampling, 8 fields per brain section were
randomly chosen in the ischemic border region under 406
magnifications on a confocal microscope. To estimate the
DCX/DAPI index, DAPI-positive and DCX-positive cells were
quantified in an area of 300 microns from the ischemic border
region at the per-infarct zone 28 days after cell transplantation
(the ischemic border was defined by histological characteristics,
mainly by the presence of edematous tissue in the ischemic zone
and the presence of polymorphonuclear stacked nuclei enclosing
the affected neuropil at the glial scar, which at this time point is
well established). This estimation consists in the number of
DCX+ cells divided per the total amount of cells (counted by
their nuclei, which is stained with DAPI). Quantification was
performed under blind condition.
Tissue Processing for Semithin Sections
Animals were perfused with PBS followed by 2% PFA and 2.5%
glutaraldehyde. Brains were post-fixed overnight in the same
fixative, cut into 200 mm coronal sections, and processed for
semithin sections. 200 mm coronal sections were post-fixed in 2%
osmium tetroxide for 2 hours, rinsed, dehydrated, and embedded
in Durcupan (Fluka). To study time dependent activation of SVZ
proliferation after cell transplantation, whole hemispheres ob-
tained at different time points (2 days, 4 days, 7 days and 28 days)
were cut into 1.5 mm semithin sections with a diamond knife and
stained with 1% toluidine-blue.
Statistical Analysis
Statistical significance was assessed by one-way or two-way
analysis of variance (ANOVA) followed by the Bonferroni post hoc
test using PASW Statistics 17.0 softwareH. A probability of P,0.05
was adopted for statistical significance. Data are reported as mean
6 SD.
Results
Survival and Migration of Transplanted Cells after
Intrastriatal Transplantation
BALB/Ca-RAG22/2cc2/2 mice received an intracranial graft
of 26105 hMAPCs or hMSCs 2 days after MCAo. Using
antibodies against human nuclei, hMSCs and hMAPCs were
clearly detected after 2 days in the transplant area. After 4 days
both cell types were primarily concentrated at the transplantation
site while migration of some cells towards the ischemic lesion was
observed. However, 7 days after transplantation there was a
decrease in the number of cells being detected both in the area of
injection, as well as, in the ischemic lesion. No cells were detected
at 28 days post-transplantation in the brain (Figure S3 and data
not shown).
Transplantation of hMAPCs and hMSCs is Associated with
a Reduced Loss of Brain Tissue
Ischemic damage leads to loss of brain tissue and the
development of various sizes of cysts in stroke mice (Fig. 1A).
Interestingly, a significant decrease (P,0.05) in tissue loss was
observed after 28 days in animals treated with hMSCs, as well as,
hMAPCs (7.75%60.8 and 6.9%61.6, respectively) compared to
the PBS-treated group of mice (12%62.8%), suggesting a
neuroprotective effect within the ischemic penumbra associated
with cell transplantation (Fig. 1B).
Cell Transplantation Induced an Increase in Angiogenesis
after Stroke
Increased vascularization in the penumbra after stroke is
associated with neurological recovery and offers another potential
target for cell therapy [38,39]. Because recent a number of studies
hMAPCs and hMSCs Transplantation after Ischemia
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have demonstrated that hMSC transplantation after stroke may
induce angiogenesis [10,11,40], which may be related to the
decrease in tissue damage, we decided to analyze blood vessel
density.
An increase in blood vessel density was found in the PBS-treated
group animals, indicating that angiogenesis is a normal response to
the ischemic injury. However, cell transplantation induced a
significative increase in blood vessel density (hMSCs:
5.37%60.09, 5.61%60.29, 5.87%60.16, 5.42%60.36; and
hMAPCs: 5.93%60.3, 6%60.61, 6.7661.2 and 6.02%60.48,
at 2 days, 4 days, 7 days and 28 days respectively) compared to the
PBS-treated group of mice (5.06%60.22%, 5.33%60.15,
5.760.06% and 5.1460.25%), p,0.05 and p,0.001. Importantly,
hMAPCs produced a significant higher effect on neovasculariza-
tion than hMSCS, p,0.001 (Fig. 2A–B), suggesting that hMAPC
exert a more robust effect on neovascularization.
Transplantation of hMAPCs and hMSCs is Associated with
Attenuation of the Inflammatory Response
An inflammatory response in the brain is associated with
changes in the shape of microglia. Under normal conditions,
microglia show a ramified appearance with a large number of
processes. In inflamed brain, microglia acquire a rounded
amoeboid shape and the length and number of processes is
decreased [41]. To determine the effect of cell transplantation on
the inflammatory response, immunostaining against Iba1 was
performed 4 days after cell transplantation. Qualitatively, a
decrease in the number and the grade of activation (reduced
somata size and increase in the ramification of the cytoplasmic
processes) was observed after cell transplantation compared to the
PBS-treated group of mice (Fig. 3A).
To quantify the effects of hMSCs and hMAPCs on microglial
activation, the total number of intersections and the percentage of
intersections per ring were estimated with a grid of concentric
circles, 5 mm apart. Although an increase in the number of
intersections was found after treatment with hMSCs and hMAPCs
(9.7861.18 and 10.8861.47, respectively) in comparison with the
PBS-treated mice (7.8660.35) (Fig. 3B), these differences with PBS
treated mice only reached significance for hMAPC treated mice
(p,0.05). Further, in PBS-treated animals a higher percentage of
intersections per ring in the first and second ring were found
(shorter processes), while in animals treated with hMSCs more
intersections were present in the second and third ring; and the
intersections in animals treated with hMAPCs were mostly found
in the distal rings (Fig. 3C). These results suggest a more
pronounced attenuation of the inflammatory response of hMAPCs
in comparison to hMSCs or PBS.
As transplantation of hMSCs in stroke models has been
associated not only with a decrease in inflammation, but also
reduced scarring [5,15], we analyzed the effect of cell transplan-
tation on scar formation by immunostaining against fibronectin
and NG2-CSP. A decrease in expression of both proteins was
observed 4 days after cell transplantation (p,0.01) (Fig. 4),
indicating the potential of hMAPCs and hMSCs to provide a
neuroprotective effect, minimizing neuronal injury and glial scar
formation.
Transplantation of hMAPCs and hMSC is Associated with
an Increase in Endogenous Regeneration due to SVZ
Proliferation
Ischemic stroke triggers increased neuroprecursor cell prolifer-
ation in the SVZ and migration of these newly formed neuroblasts
towards the damaged area, in an attempt to self-repair after the
ischemic insult [42,43,44].
To examine whether cell therapy with hMAPCs or hMSCs
could contribute to this effect, a single dose of BrdU was
administered at different time points before sacrifice in the 3
groups of mice, and the activation of cell proliferation in the SVZ
was quantified. Transplantation of both cell types produced a
significant enhancement of proliferation in the SVZ (hMSCs:
133.8363.82, 110.2463.69, 99.4264.26, 64,8764.52 cells/sec-
tion; and hMAPCs: 156.4667.9, 122.6766.42, 107.0866.98,
77.4662 cells/section, at 2 days, 4 days, 7 days and 28 days after
cell transplantation respectively) in comparison to PBS-treated
mice (12662.69, 100.4263.7, 94.8362.37 and 56.7964.11 cells/
section) (p,0.005) (Fig. 5A). Importantly, proliferation was
significantly higher in the hMAPC compared with hMSC treated
Figure 1. Effect of transplantation of hMSCs and hMAPCs in
tissue loss. A) Nissl-staining photomicrographs of coronal sections
that show the loss of tissue at 28 days after transplantation. The dashed
line marks tissue loss. Scale bar = 1000 mm; B) Quantification of tissue
loss 28 days after cell transplantation n = 4 *p,0.05 PBS-treated group
vs cell transplanted groups by Bonferroni test.
doi:10.1371/journal.pone.0043683.g001
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animals, p,0.005 (Fig. 5A), suggesting that hMAPCs exert a more
robust effect on activation of SVZ proliferation.
Activation of SVZ cell proliferation following cell transplanta-
tion was confirmed by the analysis of the upper third of the SVZ in
semithin sections. The 2–3 cell layers characteristic of wt mice
SVZ increased after stroke and PBS or cell transplantation. Within
each group, activation was higher 2 days after cell transplantation,
decreasing progressively at latter time points. 2 days after cell
transplantation, activation of cell proliferation resulted in an
increase of the number of cells as well as in the number of cells
layers to 4–5 cells thickness. Qualitatively, mice treated with
hMAPCs showed a greater activation of SVZ proliferation than
animals treated with hMSCs or PBS as the number of cells and cell
layers is higher at all time points analyzed (2 days, 4 days, 7 days
and 28 days after PBS or cell transplantation (Fig. 5B). Activation
of cell proliferation decreases progressively with time, decreasing
the number of cells and cell layers in the SVZ. However, at all the
time points analyzed the number of cell and cells layers is higher
when stem cells are transplanted compared to PBS, and more
pronounced for hMAPCs. These results are in agreement with the
quantification of BrdU+ cells in the SVZ.
Finally, to determine whether transplantation of hMSCs and
hMAPCs promotes migration and survival of endogenous cells in
the ischemic brain, double immunostaining against DCX (a
marker of immature or early neurons) and HuNu (to identify
transplanted cells) was performed 28 days after transplantation. As
previously described no transplanted cells were detected after 28
days. On the other hand, an increase in the number of DCX
positive cells was found in the scar boundary zone in animals
treated with hMAPCs and hMSCs in comparison to PBS-treated
Figure 2. Transplantation of hMSCs and hMAPCs induced an increase in angiogenesis. A) CD31 immunostaining in the ischemic boundary
zone at different time points after cell transplantation (2 days, 4 days, 7 days and 28 days) (Scale bar = 100 mm). B) Quantitative analysis of
angiogenesis after cell transplantation (n = 4). *p,0.05 and ** p,0.001 by Bonferroni test.
doi:10.1371/journal.pone.0043683.g002
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mice (Fig. 6A–C). Estimation of the DCX/DAPI index confirmed
the increase of DCX+ cells (PBS: 0.00560.003; hMSCs:
0.01560.003 and hMAPCs: 0.02160.006). However, this differ-
ence only reached significance when we compared hMAPCs to
PBS-treated animals (p,0.05) (Fig. 6D). Interestingly, hMAPCs
appear to induce more neuroblast survival in the scar boundary
zone raising the possibility of additional neurogenic effects.
Discussion
Transplantation of MSCs has been successfully used for the
treatment of experimental stroke paving the way for the initial
clinical studies in patients with ischemic stroke [22,23,24].
Administration of MSCs either intravenously or directly in the
periphery of the infarct induces a functional benefit that is
associated with pleiotropic effects including the enhancement of
neurogenesis and angiogenesis, as well as, positive effects on glial
induced scarring and axonal regeneration [1,11,14,15,16,17]. The
direct comparison of hMSC with a new population of bone
marrow derived cells, hMAPCs, indicates that the latter compared
favorably with hMSC and provides a greater beneficial effect as
indicated by the increase in angiogenesis, SVZ cell proliferation
and decreased inflammatory response providing an attractive new
source of allogeneic source of cells for stroke.
In order to examine clinical grade cell therapy products, we
chose an immunodeficient mouse model (BALB/Ca-RAG 22/2
cC2/2) that allowed us to transplant human cells [45] in an
Figure 3. Effect of hMSCs and hMAPCs transplantation on microglia activation after stroke. A) Immunostaining with anti-Iba1 in sections
corresponding to the peri-infarct zone 2 days after cell transplantation. Upper panel represents a panoramic view (Scale bar = 50 mm) while a detail
image is provided in the lower panel (Scale bar = 10 mm). B) Quantification of the mean number of intersections of microglial processes/cell with the
grid. C) Representation of the percentage of intersections with each concentric circle of the grid/cell. *p,0.05 for PBS-treated group vs. hMAPCs by
Bonferroni test.
doi:10.1371/journal.pone.0043683.g003
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immune permissive milieu, avoiding cell rejection, enabling
transplanted cell to survive longer and elicit their beneficial effects
via the release of trophic factors that enhance the recovery. The
lack of a normal inflammatory response in these animals could be
considered a limitation of our model, as not only local
inflammatory cells (glial cells) but also systemic cells participate
in the healing process after stroke. Nevertheless, the use of the
PBS-treated group of animals (injected with PBS alone) supports
our observations regarding hMAPCs and hMSCs as capable of
providing a neurorestorative effect after stroke.
hMSCs and hMAPCs engrafted short term and migrated from
the site of transplantation to the injured tissue as early as 4 days
after cell transplantation, surviving for at least 14 days post-
injection. It is known that SDF-1/CXCR4 plays a role in
mediating hMSCs migration to damaged tissue, given that SDF-
1 becomes up-regulated in the ischemic boundary zone and
hMSCs express its receptor CXCR4 [17]. We postulate that
hMAPCs also express CXCR4 and migrate in a similar way, as
this mechanism has been described not only for MSCs, but also for
NSCs and EPCs [3].
Figure 4. Glial-scar inhibitory effect after hMSCs and hMAPCs transplantation. Immunoflurescence analysis of fibronectin (A) and NG2-CSP
(B) 4 days after hMSCs and hMAPCs transplantation. The intensity of the staining varied according to the color scale shown in the left corner in each
panel. C) Quantitative analysis of NG2-CSP immunostaining. *P,0.01 in PBS-treated group vs cell transplanted groups. Scale bar = 100 mm.
doi:10.1371/journal.pone.0043683.g004
hMAPCs and hMSCs Transplantation after Ischemia
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In this study human cells disappeared progressively and were no
longer detected 4 weeks after transplantation, in contrast to other
studies where transplanted cells persisted longer. These differences
could be due to the cell type used (embryonic cells, NSCs, MSCs,
MAPCs…), the method of administration, the total number
transplanted cells (26105–26106) and, most interestingly, the time
point of administration. As we grafted the cells early after stroke,
significantly more inflammation was present compared with later
time points following stroke, constituting a more hostile environ-
ment for the transplanted cells [4,17,46,47,48]. We purposefully
grafted the cells on day 2, to impact most profoundly on the
inflammation. However, the micro environmental inflammatory-
ischemic conditions may explain why the transplanted cells
disappeared.
The issues that need to be solved before moving to the clinical
application of cell therapy in ischemic stroke have been recently
discussed and constitute the road map for the STEPS consortium
[7,49]. Among these issues, the mechanism contributing to
neuroprotection and/or neuroregeneration is not fully understood.
One of the major therapeutic effects of cell therapy in stroke is the
support of the cells to angiogenesis, in part due to the upregulation
of angiogenic growth factors and receptors, such as VEGF,
VEGFR and angiopoietins [5]. In the current study, we did not
examine the production of angiogenic growth factors from MSCs
or MAPCs but as previously shown, both human and mouse
Figure 5. Endogenous neural stem cell activation after hMSCs and hMAPCs transplantation. A) Quantification of BrdU+ cells in the SVZ at
different time points (2 days, 4 days, 7 days and 28 days) after hMSCs and hMAPCs transplantation. Cells were counted in the ipsilateral side of the
ischemic brains and in non-ischemic brains (control). *p,0.05 by Bonferroni test. B) Sections corresponding to the upper third of the SVZ that shows
the degree of proliferation of the SVZ at different time points after PBS, hMSCs and hMAPCs transplantation. Scale bar = 20 mm.
doi:10.1371/journal.pone.0043683.g005
Figure 6. Endogenous neuroblast survival. A–C) Double immunostaining against DCX (green), HuNu (red) and DAPI (blue) in the peri-infarct
zone 28 days after cell tranplantation. Scale bar = 50 mm. Magnification scale bar = 75 mm. D) Representation of the DCX/DAPI index estimated in the
scar boundary zone 28 days after hMSCs and hMAPCs transplantation. *p,0.05 for PBS-treated group vs hMAPCs by Bonferroni test.
doi:10.1371/journal.pone.0043683.g006
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MAPCs produce significant amounts of VEGF, PlGF, bFGF,
PDGF-BB and even TGF-b, all of which are implicated in angio-
vasculogenesis [50,51]. We hypothesize that higher levels of these
growth factors in hMAPCs versus hMSCs could explain the
greater effect observed in animals treated with hMAPCs.
Another potential repair mechanism is the ability of hMSCs and
hMAPCs to attenuate the robust inflammatory response, which
takes place within hours after stroke and represents a key factor for
brain damage. This idea is supported by the analyses of microglial
activation 4 days after cell transplantation, which demonstrated a
significant reduction in the degree of activation. Interestingly, it
has been demonstrated that rMAPCs release anti-inflammatory
cytokines, such as IL-4 and IL-10, that regulate microglia in vitro
[52], and thus could be responsible for the reduced activation of
microglia in mice treated with hMAPCs in comparison with
hMSCs. MSCs have been described to substantially reduce
expression of axonal-growth inhibitory proteins, such as reticulon
(Rtn4; also known as Nogo), enabling axonal and neurite
outgrowth [53] both in vitro and in vivo, so it is tempting to
speculate that transplantation of MAPCs is associated with similar
effects contributing to axonal regeneration. The reduction in the
scar and the marked decrease in both NG2-CSP and fibronectin
expression could provide a more permissive environment, further
promoting axonal sprouting with new connections being estab-
lished, eventually leading to improvement in neurological func-
tion.
Stroke promotes cell proliferation in the SVZ and increases the
number of immature neurons that migrate into the severely
damaged area [42,44]. However, the vast majority of these cells
usually die. This degeneration probably reflects the detrimental
effects of the severely damaged tissue, which lacks appropriate
trophic support and connections. Our results demonstrate that
hMSCs and hMAPCs enhanced SVZ proliferation and neuroblast
survival by mechanisms likely related to the capacity of the cells to
act as small biological pumps that secrete neurotrophins (BDNF),
cytokines, and growth factors (VEGF, bFGF, NGF) with
autocrine, as well as paracrine effects, on resident cells [54]. It is
important to point out that neurogenesis and angiogenesis are
highly interdependent processes. Activated endothelial cells secrete
many factors such as stromal-derived factor 1a and matrix
metalloproteinases (MMPs) that mediate neuroblast migration and
survival, attracting neuroblasts from the SVZ and probably into a
lesser extent from the striatal parenchyma (dormant neurons or
latent progenitors) to the boundary zone of the ischemic lesion
while the release of MMPs allows for the degradation of the
extracellular matrix. In addition to guiding neuroblast migration,
activated endothelial cells secrete VEGF that increases neurogen-
esis [47]. The fact that hMAPCs induced an increase in
angiogenesis in comparison with hMSCs could also explain the
greater effect on SVZ proliferation and neuroblast survival.
Conclusions
In summary, we demonstrate that transplantation of hMSCs
and hMAPCs mediate neuroprotection during the acute phase of
ischemic stroke and prevents delayed brain injury through several
therapeutic effects, such as angiogenesis, diminished inflammation
and scarring, as well as, increased SVZ cell proliferation and
neuroblast survival close to the ischemic area. Therapeutic effects
mediated by cell transplantation do not require long-term cell
engraftment and are likely related to the secretion of growth
factors and cytokines. Experimental data suggest that hMAPCs
clone (B30/E2) may produce greater therapeutic effects in
comparison with hMSCs clone (JN2) and raising the possibility
to use hMAPCs as an alternative source of cells for transplantation
in patients suffering from stroke given their therapeutic potential
and the possibility of producing them under GMP conditions.
However, prior to making these assumptions more clones of
hMSCs and hMAPCs should be compared.
Supporting Information
Figure S1 Characterization of hMSCs and hMAPCs by
flow cytometry. Cells from MAPC clone B30A2 and MSC
clone JN1 were stained with antibodies against CD44, CD45,
HLA-II, CD144, CD34, HLA-I, CD105, CD140a, CD90, CD73,
CD117, and CD31 (blue line) or isotype controls (black line).
(TIF)
Figure S2 Experimental design. Diagram with the groups,
animal per group and time points analyzed.
(TIF)
Figure S3 hMSCs and hMAPCs survival and migration.
Anti-human nuclei immunostaining to detect human cells after 2
days and 7 days of transplantation. A–B higher magnification
pictures of depicted squares in the panoramic views. Panoramic
view scale bar = 500 mm. Magnification scale bar = 100 mm.
(TIF)
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